FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891915572> ?p ?o ?g. }

• W2891915572 endingPage "151" @default.
• W2891915572 startingPage "142" @default.
• W2891915572 abstract "Purpose Therapeutic radiation has conflicting immune effects: radiation therapy (RT)-induced immunogenic cell death can contribute to immune response, but lymphocytes are also sensitive to RT. It is unknown whether palliative RT leads to lymphopenia in patients treated with immune checkpoint inhibitors (ICIs) and whether this affects outcomes. As such, we sought to assess the impact of palliative RT on circulating lymphocyte count and neutrophil-to-lymphocyte ratio in patients being treated with PD-1–directed ICI and associations with survival. Methods and Materials We identified patients from 5 radiation oncology centers, treated with palliative RT and either pembrolizumab or nivolumab with non-small cell lung cancer, metastatic melanoma, and renal cell carcinoma. Patients who received intervening cytotoxic chemotherapy were excluded. We recorded absolute lymphocyte count (ALC) and neutrophil-to-lymphocyte ratio before and after palliative RT and at the start of ICI. Survival was analyzed using the Kaplan-Meier method and Cox proportional hazard models. Results One hundred ten patients received 225 courses of palliative RT. Median change in ALC after RT was –161 cells/mL. Decreases in ALC were greater with RT to the spine, lung/mediastinum, and chest wall compared with the brain, extremity, or abdomen/pelvis (P = .002) and after courses >5 fractions (P = .003). Extracranial and >5-fraction RT was associated with increased odds of severe lymphopenia (ALC <500) at the end of RT (odds ratio [OR], 3.7; P = .001; and OR, 3.9; P = .001, respectively). Patients who developed RT-induced severe lymphopenia were more likely to have severe lymphopenia when ICI was initiated (OR, 6.4; P = .0001), particularly when RT was administered in the previous 3 months (OR, 189; P < .0001). Severe lymphopenia at onset of ICI therapy was associated with increased mortality on multivariable analysis (hazard ratio, 2.1; P = .03). Conclusions Extracranial or prolonged courses of RT increase the risk of severe lymphopenia, which is associated with poorer survival in patients treated with ICI. Therapeutic radiation has conflicting immune effects: radiation therapy (RT)-induced immunogenic cell death can contribute to immune response, but lymphocytes are also sensitive to RT. It is unknown whether palliative RT leads to lymphopenia in patients treated with immune checkpoint inhibitors (ICIs) and whether this affects outcomes. As such, we sought to assess the impact of palliative RT on circulating lymphocyte count and neutrophil-to-lymphocyte ratio in patients being treated with PD-1–directed ICI and associations with survival. We identified patients from 5 radiation oncology centers, treated with palliative RT and either pembrolizumab or nivolumab with non-small cell lung cancer, metastatic melanoma, and renal cell carcinoma. Patients who received intervening cytotoxic chemotherapy were excluded. We recorded absolute lymphocyte count (ALC) and neutrophil-to-lymphocyte ratio before and after palliative RT and at the start of ICI. Survival was analyzed using the Kaplan-Meier method and Cox proportional hazard models. One hundred ten patients received 225 courses of palliative RT. Median change in ALC after RT was –161 cells/mL. Decreases in ALC were greater with RT to the spine, lung/mediastinum, and chest wall compared with the brain, extremity, or abdomen/pelvis (P = .002) and after courses >5 fractions (P = .003). Extracranial and >5-fraction RT was associated with increased odds of severe lymphopenia (ALC <500) at the end of RT (odds ratio [OR], 3.7; P = .001; and OR, 3.9; P = .001, respectively). Patients who developed RT-induced severe lymphopenia were more likely to have severe lymphopenia when ICI was initiated (OR, 6.4; P = .0001), particularly when RT was administered in the previous 3 months (OR, 189; P < .0001). Severe lymphopenia at onset of ICI therapy was associated with increased mortality on multivariable analysis (hazard ratio, 2.1; P = .03). Extracranial or prolonged courses of RT increase the risk of severe lymphopenia, which is associated with poorer survival in patients treated with ICI." @default.
• W2891915572 created "2018-09-27" @default.
• W2891915572 creator A5002159135 @default.
• W2891915572 creator A5008974264 @default.
• W2891915572 creator A5016683612 @default.
• W2891915572 creator A5022535771 @default.
• W2891915572 creator A5022694627 @default.
• W2891915572 creator A5024024612 @default.
• W2891915572 creator A5041066193 @default.
• W2891915572 creator A5043519166 @default.
• W2891915572 creator A5047888321 @default.
• W2891915572 creator A5049994818 @default.
• W2891915572 creator A5051390263 @default.
• W2891915572 creator A5053368351 @default.
• W2891915572 creator A5080783554 @default.
• W2891915572 creator A5084967339 @default.
• W2891915572 date "2019-01-01" @default.
• W2891915572 modified "2023-10-07" @default.
• W2891915572 title "The Impact of Radiation Therapy on Lymphocyte Count and Survival in Metastatic Cancer Patients Receiving PD-1 Immune Checkpoint Inhibitors" @default.
• W2891915572 cites W1484334610 @default.
• W2891915572 cites W1757492577 @default.
• W2891915572 cites W1893566975 @default.
• W2891915572 cites W1919200564 @default.
• W2891915572 cites W2002968221 @default.
• W2891915572 cites W2008259119 @default.
• W2891915572 cites W2013043293 @default.
• W2891915572 cites W2023322050 @default.
• W2891915572 cites W2024861438 @default.
• W2891915572 cites W2025310622 @default.
• W2891915572 cites W2032166347 @default.
• W2891915572 cites W2047866259 @default.
• W2891915572 cites W2062029576 @default.
• W2891915572 cites W2083984828 @default.
• W2891915572 cites W2092233067 @default.
• W2891915572 cites W2100158834 @default.
• W2891915572 cites W2104347254 @default.
• W2891915572 cites W2104750134 @default.
• W2891915572 cites W2107484016 @default.
• W2891915572 cites W2118389381 @default.
• W2891915572 cites W2124995644 @default.
• W2891915572 cites W2126834976 @default.
• W2891915572 cites W2127199535 @default.
• W2891915572 cites W2128035403 @default.
• W2891915572 cites W2134426002 @default.
• W2891915572 cites W2135636445 @default.
• W2891915572 cites W2137930630 @default.
• W2891915572 cites W2139758621 @default.
• W2891915572 cites W2143853878 @default.
• W2891915572 cites W2152897456 @default.
• W2891915572 cites W2159861935 @default.
• W2891915572 cites W2166662937 @default.
• W2891915572 cites W2222086386 @default.
• W2891915572 cites W2225975747 @default.
• W2891915572 cites W2296049142 @default.
• W2891915572 cites W2434730538 @default.
• W2891915572 cites W2497169534 @default.
• W2891915572 cites W2511833681 @default.
• W2891915572 cites W2587330058 @default.
• W2891915572 cites W2618641368 @default.
• W2891915572 cites W2624275086 @default.
• W2891915572 cites W2715315455 @default.
• W2891915572 cites W2749105855 @default.
• W2891915572 cites W2753065806 @default.
• W2891915572 cites W2759495409 @default.
• W2891915572 cites W2773643507 @default.
• W2891915572 cites W2783295481 @default.
• W2891915572 cites W2790712053 @default.
• W2891915572 cites W2805209851 @default.
• W2891915572 cites W2883706035 @default.
• W2891915572 doi "https://doi.org/10.1016/j.ijrobp.2018.09.010" @default.
• W2891915572 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30227198" @default.
• W2891915572 hasPublicationYear "2019" @default.
• W2891915572 type Work @default.
• W2891915572 sameAs 2891915572 @default.
• W2891915572 citedByCount "104" @default.
• W2891915572 countsByYear W28919155722019 @default.
• W2891915572 countsByYear W28919155722020 @default.
• W2891915572 countsByYear W28919155722021 @default.
• W2891915572 countsByYear W28919155722022 @default.
• W2891915572 countsByYear W28919155722023 @default.
• W2891915572 crossrefType "journal-article" @default.
• W2891915572 hasAuthorship W2891915572A5002159135 @default.
• W2891915572 hasAuthorship W2891915572A5008974264 @default.
• W2891915572 hasAuthorship W2891915572A5016683612 @default.
• W2891915572 hasAuthorship W2891915572A5022535771 @default.
• W2891915572 hasAuthorship W2891915572A5022694627 @default.
• W2891915572 hasAuthorship W2891915572A5024024612 @default.
• W2891915572 hasAuthorship W2891915572A5041066193 @default.
• W2891915572 hasAuthorship W2891915572A5043519166 @default.
• W2891915572 hasAuthorship W2891915572A5047888321 @default.
• W2891915572 hasAuthorship W2891915572A5049994818 @default.
• W2891915572 hasAuthorship W2891915572A5051390263 @default.
• W2891915572 hasAuthorship W2891915572A5053368351 @default.
• W2891915572 hasAuthorship W2891915572A5080783554 @default.
• W2891915572 hasAuthorship W2891915572A5084967339 @default.
• W2891915572 hasConcept C121608353 @default.
• W2891915572 hasConcept C126322002 @default.
• W2891915572 hasConcept C143998085 @default.

• next